The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients (NCT04525313) | Clinical Trial Compass
UnknownNot Applicable
The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients
116 participantsStarted 2020-08
Plain-language summary
establishment and validation of the prediction model of avastin plus chemotherapy as first line treatment in simultaneous ras mutant unresectable CRLM patients
Who can participate
Age range18 Years – 79 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
age 18-75 years, histologically proven colorectal adenocarcinoma, with liver-dominant disease, a life expectancy of \> 3 months, ras mutation, unresectable simultaneous liver metastasis, ECOG 0-1, written informed consent for participation in the trial.
Exclusion Criteria:
patients with known hypersensitivity reactions to any of the components of the study treatments, pregnancy or breast-feeding, accepted chemotherapy, radiotherapy and target therapy before primary tumor resection, other previous malignancy within 5 years, known drug abuse/alcohol abuse, ECOG\>1, legal incapacity or limited legal capacity.